Charles River Laboratories (CRL) investor relations material

Leadership transition and strategic focus

• New CEO with over 30 years at the company reports a smooth transition, emphasizing stakeholder engagement and alignment with the 'Pathway to Purpose' strategy.

• Recent leadership changes bring fresh perspectives, with a focus on modernizing operations, refining the portfolio, and client-centric growth.

• Leadership team is actively visiting sites and engaging with employees and clients to ensure strategy execution.

• Investor Day is scheduled for next week to provide further strategic and operational updates.

Financial performance and outlook

• Recent quarters showed strong net book-to-bill ratios above 1.1, with a notable 1.19 in the last quarter, leading to raised guidance for organic growth and EPS.

• Backlog, which had eroded in previous years, is now being rebuilt, supporting a positive outlook for the second half of the year.

• Financial targets for each segment will be detailed at Investor Day, with a focus on realistic, achievable goals based on current execution.

• Margin expansion is expected, particularly in the Manufacturing and Commercialization segment, which is approaching 40% margins.

Operational improvements and market dynamics

• Modernization efforts include automation and efficiency improvements to reduce manual processes and enhance productivity.

• The company is not leading on price discounting but is focused on aggressive proposal follow-up, optimized portfolio, and rapid project start times to win business.

• AI-driven drug development is seen as a future tailwind, but current volume impact is limited.

• Demand for complex modalities, including cell and gene therapy, is increasing, driving demand for scientific and analytical services.